+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Familial Adenomatous Polyposis Treatment Market by Treatment Type (Combination Therapy, Endoscopic Surveillance, Pharmacologic Therapy), Route Of Administration (Intravenous, Oral, Subcutaneous), Distribution Channel, End User, Indication - Global Forecast 2025-2030- Product Image
Familial Adenomatous Polyposis Treatment Market by Treatment Type (Combination Therapy, Endoscopic Surveillance, Pharmacologic Therapy), Route Of Administration (Intravenous, Oral, Subcutaneous), Distribution Channel, End User, Indication - Global Forecast 2025-2030- Product Image
Sale

Familial Adenomatous Polyposis Treatment Market by Treatment Type (Combination Therapy, Endoscopic Surveillance, Pharmacologic Therapy), Route Of Administration (Intravenous, Oral, Subcutaneous), Distribution Channel, End User, Indication - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 198 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5967598
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Familial Adenomatous Polyposis Treatment Market is evolving rapidly, influenced by advances in research, regulatory shifts, and an increased emphasis on patient-centric care. Executives seeking informed decisions on investments, partnerships, and growth strategies need clear, actionable insights into the current market framework and future trajectory.

Market Snapshot: Familial Adenomatous Polyposis Treatment Market Overview

The Familial Adenomatous Polyposis Treatment Market grew from USD 1.20 billion in 2024 to USD 1.29 billion in 2025. It is expected to continue growing at a CAGR of 7.47%, reaching USD 1.86 billion by 2030. This growth reflects accelerated innovation and increased adoption of advanced genetic and endoscopic interventions across key global regions.

Scope & Segmentation

This comprehensive report examines the Familial Adenomatous Polyposis Treatment Market, segmenting it by treatment modalities, routes of administration, distribution channels, end users, and disease indication. The analysis spans major regions and evaluates the competitive positioning of leading industry participants.

  • Treatment Type: Includes combination therapy, endoscopic surveillance (colonoscopy, sigmoidoscopy), pharmacologic therapy (biologics, gene therapy, monoclonal antibodies, nonsteroidal anti-inflammatory drugs, COX-2 inhibitors, nonselective NSAIDs), and surgical interventions (colectomy, ileorectal anastomosis, proctocolectomy).
  • Route of Administration: Intravenous, oral, and subcutaneous delivery formats for enhanced patient convenience.
  • Distribution Channel: Hospital pharmacies, online pharmacies, retail pharmacies—with each channel catering to distinct product types and provider needs.
  • End User: Settings include home care, hospitals, and specialty clinics, reflecting diverse care models.
  • Indication: Differentiates between attenuated and classic forms of familial adenomatous polyposis for targeted treatment approaches.
  • Regional Coverage: Analysis includes the Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, among others), and Asia-Pacific (China, India, Japan, Australia, South Korea, and additional markets).
  • Key Companies: Profiles organizations such as Ambry Genetics Corporation by Tempus Company, Eloxx Pharmaceuticals, Emtora Biosciences, KD Pharma Group, Biodexa Pharmaceuticals, Thermo Fisher Scientific, Labcorp, Olympus Corporation, Medtronic, Stryker, Recursion Pharmaceuticals, BGI Genomics, and more.

Secondary Keyword Integration

Precision medicine, digital health integration, and adaptive regulatory pathways are increasingly shaping market strategies. Companies are leveraging these tools to address both clinical and economic stakeholder priorities across established and emerging economies.

Key Takeaways

  • Molecular diagnostics are refining patient identification and supporting individualized treatment programs.
  • Digital health tools enable remote surveillance, improving adherence and generating valuable real-world evidence for value-based contracting.
  • Strategic partnerships across biopharma, device firms, and payers streamline access and foster greater operational agility.
  • Variation in reimbursement, regulatory protocols, and health technology assessments requires adaptive region-specific strategies for sustainable growth.
  • Patient support initiatives and pharmacovigilance infrastructures are becoming essential to track long-term efficacy and safety outcomes.
  • The convergence of gene therapy, advanced imaging, and personalized medicine is expanding the therapeutic portfolio for familial adenomatous polyposis management.

Tariff Impact

Revised United States tariff schedules in 2025 have introduced new cost management complexities for imported biologics, endoscopic devices, and surgical instruments. These changes are prompting reassessment of procurement, supply chain, and manufacturing strategies. Companies are responding by exploring onshore manufacturing, local distribution, and tariff mitigation measures to sustain product availability and patient access.

Methodology & Data Sources

The analysis employs a multi-dimensional research framework—including secondary research from peer-reviewed journals and regulatory filings, augmented by primary insights from clinicians, payers, and patient advocates. Quantitative healthcare utilization and procurement data complement thematic qualitative analyses, triangulated and peer-reviewed for accuracy.

Why This Report Matters

  • Offers concise, actionable intelligence for senior executives seeking to optimize portfolio strategy and regional market entry.
  • Highlights emerging opportunities and potential risks, supporting informed investment and contracting decisions.
  • Equips stakeholders with authoritative evidence to guide strategic planning in a complex, highly regulated environment.

Conclusion

With the Familial Adenomatous Polyposis Treatment Market entering a new phase defined by innovation and operational complexity, this analysis delivers vital clarity for confident decision-making. Strategic adaptation and stakeholder alignment remain key for long-term success in this evolving sector.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emerging gene editing approaches for targeted suppression of APC mutations in familial adenomatous polyposis
5.2. Advancements in endoscopic surveillance techniques for earlier polyp detection in FAP patients
5.3. Clinical progression of combination therapy using COX-2 inhibitors and EGFR blockers in FAP management
5.4. Regulatory impact of orphan drug designations on novel FAP treatment development pipelines
5.5. Integration of predictive genetic profiling and personalized chemoprevention strategies in FAP care
5.6. Expansion of minimally invasive colectomy procedures and postoperative quality of life outcomes research in FAP
5.7. Emergence of biomarker-driven clinical trials evaluating targeted small molecule therapies in FAP cohorts
5.8. Digital health monitoring platforms for real-time assessment of post-surgical recurrence risk in FAP patients
5.9. Accessibility and adoption trends of next-generation NSAIDs for polyp burden reduction in global FAP markets
5.10. Strategic partnerships between biotechs and academic centers accelerating translational research in FAP therapeutics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Familial Adenomatous Polyposis Treatment Market, by Treatment Type
8.1. Introduction
8.2. Combination Therapy
8.3. Endoscopic Surveillance
8.3.1. Colonoscopy
8.3.2. Sigmoidoscopy
8.4. Pharmacologic Therapy
8.4.1. Biologics
8.4.1.1. Gene Therapy
8.4.1.2. Monoclonal Antibodies
8.4.2. Nonsteroidal Anti-Inflammatory Drugs
8.4.2.1. COX-2 Inhibitors
8.4.2.2. Nonselective NSAIDs
8.5. Surgical Intervention
8.5.1. Colectomy
8.5.2. Ileorectal Anastomosis
8.5.3. Proctocolectomy
9. Familial Adenomatous Polyposis Treatment Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous
9.3. Oral
9.4. Subcutaneous
10. Familial Adenomatous Polyposis Treatment Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Familial Adenomatous Polyposis Treatment Market, by End User
11.1. Introduction
11.2. Home Care
11.3. Hospitals
11.4. Specialty Clinics
12. Familial Adenomatous Polyposis Treatment Market, by Indication
12.1. Introduction
12.2. Attenuated FAP
12.3. Classic FAP
13. Americas Familial Adenomatous Polyposis Treatment Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Familial Adenomatous Polyposis Treatment Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Familial Adenomatous Polyposis Treatment Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Eloxx Pharmaceuticals, Inc.
16.3.2. Emtora Biosciences
16.3.3. KD Pharma Group
16.3.4. Biodexa Pharmaceuticals PLC
16.3.5. Thermo Fisher Scientific Inc.
16.3.6. Olympus Corporation
16.3.7. FUJIFILM Holdings Corporation
16.3.8. Pentax Ricoh Imaging Company, Ltd.
16.3.9. Medtronic plc
16.3.10. Siemens Healthcare Private Limited
16.3.11. Bayer Corporation
16.3.12. Boston Scientific Corporation
16.3.13. Parabilis Medicines
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2018-2030 (USD THOUSAND)
FIGURE 3. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD THOUSAND)
FIGURE 4. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD THOUSAND)
FIGURE 5. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD THOUSAND)
FIGURE 7. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD THOUSAND)
FIGURE 9. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD THOUSAND)
FIGURE 11. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD THOUSAND)
FIGURE 13. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD THOUSAND)
FIGURE 15. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD THOUSAND)
FIGURE 17. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD THOUSAND)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD THOUSAND)
FIGURE 21. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD THOUSAND)
FIGURE 23. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET: RESEARCHAI
FIGURE 26. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET: RESEARCHSTATISTICS
FIGURE 27. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET: RESEARCHCONTACTS
FIGURE 28. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2018-2024 (USD THOUSAND)
TABLE 4. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2025-2030 (USD THOUSAND)
TABLE 5. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD THOUSAND)
TABLE 6. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY REGION, 2025-2030 (USD THOUSAND)
TABLE 7. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD THOUSAND)
TABLE 8. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD THOUSAND)
TABLE 9. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD THOUSAND)
TABLE 10. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD THOUSAND)
TABLE 11. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD THOUSAND)
TABLE 12. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2030 (USD THOUSAND)
TABLE 13. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, BY REGION, 2018-2024 (USD THOUSAND)
TABLE 14. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, BY REGION, 2025-2030 (USD THOUSAND)
TABLE 15. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COLONOSCOPY, BY REGION, 2018-2024 (USD THOUSAND)
TABLE 16. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COLONOSCOPY, BY REGION, 2025-2030 (USD THOUSAND)
TABLE 17. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SIGMOIDOSCOPY, BY REGION, 2018-2024 (USD THOUSAND)
TABLE 18. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SIGMOIDOSCOPY, BY REGION, 2025-2030 (USD THOUSAND)
TABLE 19. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2024 (USD THOUSAND)
TABLE 20. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2025-2030 (USD THOUSAND)
TABLE 21. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, BY REGION, 2018-2024 (USD THOUSAND)
TABLE 22. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, BY REGION, 2025-2030 (USD THOUSAND)
TABLE 23. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD THOUSAND)
TABLE 24. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2030 (USD THOUSAND)
TABLE 25. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD THOUSAND)
TABLE 26. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2030 (USD THOUSAND)
TABLE 27. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD THOUSAND)
TABLE 28. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD THOUSAND)
TABLE 29. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD THOUSAND)
TABLE 30. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD THOUSAND)
TABLE 31. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2024 (USD THOUSAND)
TABLE 32. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2025-2030 (USD THOUSAND)
TABLE 33. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COX-2 INHIBITORS, BY REGION, 2018-2024 (USD THOUSAND)
TABLE 34. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COX-2 INHIBITORS, BY REGION, 2025-2030 (USD THOUSAND)
TABLE 35. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSELECTIVE NSAIDS, BY REGION, 2018-2024 (USD THOUSAND)
TABLE 36. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSELECTIVE NSAIDS, BY REGION, 2025-2030 (USD THOUSAND)
TABLE 37. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD THOUSAND)
TABLE 38. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2030 (USD THOUSAND)
TABLE 39. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2024 (USD THOUSAND)
TABLE 40. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2025-2030 (USD THOUSAND)
TABLE 41. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2018-2024 (USD THOUSAND)
TABLE 42. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2025-2030 (USD THOUSAND)
TABLE 43. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COLECTOMY, BY REGION, 2018-2024 (USD THOUSAND)
TABLE 44. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COLECTOMY, BY REGION, 2025-2030 (USD THOUSAND)
TABLE 45. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ILEORECTAL ANASTOMOSIS, BY REGION, 2018-2024 (USD THOUSAND)
TABLE 46. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ILEORECTAL ANASTOMOSIS, BY REGION, 2025-2030 (USD THOUSAND)
TABLE 47. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PROCTOCOLECTOMY, BY REGION, 2018-2024 (USD THOUSAND)
TABLE 48. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PROCTOCOLECTOMY, BY REGION, 2025-2030 (USD THOUSAND)
TABLE 49. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD THOUSAND)
TABLE 50. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD THOUSAND)
TABLE 51. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD THOUSAND)
TABLE 52. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD THOUSAND)
TABLE 53. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD THOUSAND)
TABLE 54. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD THOUSAND)
TABLE 55. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD THOUSAND)
TABLE 56. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD THOUSAND)
TABLE 57. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD THOUSAND)
TABLE 58. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD THOUSAND)
TABLE 59. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD THOUSAND)
TABLE 60. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD THOUSAND)
TABLE 61. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD THOUSAND)
TABLE 62. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD THOUSAND)
TABLE 63. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD THOUSAND)
TABLE 64. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD THOUSAND)
TABLE 65. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD THOUSAND)
TABLE 66. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD THOUSAND)
TABLE 67. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD THOUSAND)
TABLE 68. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD THOUSAND)
TABLE 69. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD THOUSAND)
TABLE 70. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2025-2030 (USD THOUSAND)
TABLE 71. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD THOUSAND)
TABLE 72. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD THOUSAND)
TABLE 73. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD THOUSAND)
TABLE 74. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD THOUSAND)
TABLE 75. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2024 (USD THOUSAND)
TABLE 76. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2025-2030 (USD THOUSAND)
TABLE 77. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ATTENUATED FAP, BY REGION, 2018-2024 (USD THOUSAND)
TABLE 78. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ATTENUATED FAP, BY REGION, 2025-2030 (USD THOUSAND)
TABLE 79. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY CLASSIC FAP, BY REGION, 2018-2024 (USD THOUSAND)
TABLE 80. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY CLASSIC FAP, BY REGION, 2025-2030 (USD THOUSAND)
TABLE 81. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD THOUSAND)
TABLE 82. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD THOUSAND)
TABLE 83. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2024 (USD THOUSAND)
TABLE 84. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2025-2030 (USD THOUSAND)
TABLE 85. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2024 (USD THOUSAND)
TABLE 86. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2025-2030 (USD THOUSAND)
TABLE 87. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD THOUSAND)
TABLE 88. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD THOUSAND)
TABLE 89. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD THOUSAND)
TABLE 90. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2030 (USD THOUSAND)
TABLE 91. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD THOUSAND)
TABLE 92. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD THOUSAND)
TABLE 93. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD THOUSAND)
TABLE 94. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD THOUSAND)
TABLE 95. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD THOUSAND)
TABLE 96. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD THOUSAND)
TABLE 97. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD THOUSAND)
TABLE 98. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD THOUSAND)
TABLE 99. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2024 (USD THOUSAND)
TABLE 100. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2025-2030 (USD THOUSAND)
TABLE 101. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD THOUSAND)
TABLE 102. AMERICAS FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD THOUSAND)
TABLE 103. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD THOUSAND)
TABLE 104. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD THOUSAND)
TABLE 105. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2024 (USD THOUSAND)
TABLE 106. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2025-2030 (USD THOUSAND)
TABLE 107. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2024 (USD THOUSAND)
TABLE 108. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2025-2030 (USD THOUSAND)
TABLE 109. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD THOUSAND)
TABLE 110. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD THOUSAND)
TABLE 111. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD THOUSAND)
TABLE 112. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2030 (USD THOUSAND)
TABLE 113. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD THOUSAND)
TABLE 114. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD THOUSAND)
TABLE 115. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD THOUSAND)
TABLE 116. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD THOUSAND)
TABLE 117. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD THOUSAND)
TABLE 118. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD THOUSAND)
TABLE 119. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD THOUSAND)
TABLE 120. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD THOUSAND)
TABLE 121. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2024 (USD THOUSAND)
TABLE 122. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2025-2030 (USD THOUSAND)
TABLE 123. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY STATE, 2018-2024 (USD THOUSAND)
TABLE 124. UNITED STATES FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY STATE, 2025-2030 (USD THOUSAND)
TABLE 125. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD THOUSAND)
TABLE 126. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD THOUSAND)
TABLE 127. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2024 (USD THOUSAND)
TABLE 128. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2025-2030 (USD THOUSAND)
TABLE 129. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2024 (USD THOUSAND)
TABLE 130. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2025-2030 (USD THOUSAND)
TABLE 131. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD THOUSAND)
TABLE 132. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD THOUSAND)
TABLE 133. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD THOUSAND)
TABLE 134. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2030 (USD THOUSAND)
TABLE 135. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD THOUSAND)
TABLE 136. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD THOUSAND)
TABLE 137. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD THOUSAND)
TABLE 138. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD THOUSAND)
TABLE 139. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD THOUSAND)
TABLE 140. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD THOUSAND)
TABLE 141. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD THOUSAND)
TABLE 142. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD THOUSAND)
TABLE 143. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2024 (USD THOUSAND)
TABLE 144. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2025-2030 (USD THOUSAND)
TABLE 145. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD THOUSAND)
TABLE 146. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD THOUSAND)
TABLE 147. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2024 (USD THOUSAND)
TABLE 148. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2025-2030 (USD THOUSAND)
TABLE 149. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2024 (USD THOUSAND)
TABLE 150. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2025-2030 (USD THOUSAND)
TABLE 151. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD THOUSAND)
TABLE 152. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD THOUSAND)
TABLE 153. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD THOUSAND)
TABLE 154. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2030 (USD THOUSAND)
TABLE 155. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD THOUSAND)
TABLE 156. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD THOUSAND)
TABLE 157. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD THOUSAND)
TABLE 158. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD THOUSAND)
TABLE 159. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD THOUSAND)
TABLE 160. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD THOUSAND)
TABLE 161. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD THOUSAND)
TABLE 162. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD THOUSAND)
TABLE 163. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2024 (USD THOUSAND)
TABLE 164. MEXICO FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2025-2030 (USD THOUSAND)
TABLE 165. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD THOUSAND)
TABLE 166. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD THOUSAND)
TABLE 167. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2024 (USD THOUSAND)
TABLE 168. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2025-2030 (USD THOUSAND)
TABLE 169. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2024 (USD THOUSAND)
TABLE 170. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2025-2030 (USD THOUSAND)
TABLE 171. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD THOUSAND)
TABLE 172. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD THOUSAND)
TABLE 173. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD THOUSAND)
TABLE 174. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2030 (USD THOUSAND)
TABLE 175. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD THOUSAND)
TABLE 176. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD THOUSAND)
TABLE 177. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD THOUSAND)
TABLE 178. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD THOUSAND)
TABLE 179. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD THOUSAND)
TABLE 180. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD THOUSAND)
TABLE 181. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD THOUSAND)
TABLE 182. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD THOUSAND)
TABLE 183. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2024 (USD THOUSAND)
TABLE 184. BRAZIL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2025-2030 (USD THOUSAND)
TABLE 185. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD THOUSAND)
TABLE 186. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD THOUSAND)
TABLE 187. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2024 (USD THOUSAND)
TABLE 188. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2025-2030 (USD THOUSAND)
TABLE 189. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2024 (USD THOUSAND)
TABLE 190. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2025-2030 (USD THOUSAND)
TABLE 191. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD THOUSAND)
TABLE 192. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD THOUSAND)
TABLE 193. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD THOUSAND)
TABLE 194. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2030 (USD THOUSAND)
TABLE 195. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD THOUSAND)
TABLE 196. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD THOUSAND)
TABLE 197. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD THOUSAND)
TABLE 198. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD THOUSAND)
TABLE 199. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD THOUSAND)
TABLE 200. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD THOUSAND)
TABLE 201. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD THOUSAND)
TABLE 202. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD THOUSAND)
TABLE 203. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2024 (USD THOUSAND)
TABLE 204. ARGENTINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2025-2030 (USD THOUSAND)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD THOUSAND)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD THOUSAND)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2024 (USD THOUSAND)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2025-2030 (USD THOUSAND)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2024 (USD THOUSAND)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2025-2030 (USD THOUSAND)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD THOUSAND)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD THOUSAND)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD THOUSAND)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2030 (USD THOUSAND)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD THOUSAND)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD THOUSAND)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD THOUSAND)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD THOUSAND)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD THOUSAND)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD THOUSAND)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD THOUSAND)
TABLE 222. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD THOUSAND)
TABLE 223. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2024 (USD THOUSAND)
TABLE 224. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2025-2030 (USD THOUSAND)
TABLE 225. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD THOUSAND)
TABLE 226. EUROPE, MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD THOUSAND)
TABLE 227. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD THOUSAND)
TABLE 228. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD THOUSAND)
TABLE 229. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2024 (USD THOUSAND)
TABLE 230. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2025-2030 (USD THOUSAND)
TABLE 231. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2024 (USD THOUSAND)
TABLE 232. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2025-2030 (USD THOUSAND)
TABLE 233. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD THOUSAND)
TABLE 234. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD THOUSAND)
TABLE 235. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD THOUSAND)
TABLE 236. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2030 (USD THOUSAND)
TABLE 237. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD THOUSAND)
TABLE 238. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD THOUSAND)
TABLE 239. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD THOUSAND)
TABLE 240. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD THOUSAND)
TABLE 241. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD THOUSAND)
TABLE 242. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD THOUSAND)
TABLE 243. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD THOUSAND)
TABLE 244. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD THOUSAND)
TABLE 245. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2018-2024 (USD THOUSAND)
TABLE 246. UNITED KINGDOM FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY INDICATION, 2025-2030 (USD THOUSAND)
TABLE 247. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD THOUSAND)
TABLE 248. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD THOUSAND)
TABLE 249. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2018-2024 (USD THOUSAND)
TABLE 250. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ENDOSCOPIC SURVEILLANCE, 2025-2030 (USD THOUSAND)
TABLE 251. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2024 (USD THOUSAND)
TABLE 252. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2025-2030 (USD THOUSAND)
TABLE 253. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD THOUSAND)
TABLE 254. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD THOUSAND)
TABLE 255. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD THOUSAND)
TABLE 256. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2030 (USD THOUSAND)
TABLE 257. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD THOUSAND)
TABLE 258. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2030 (USD THOUSAND)
TABLE 259. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD THOUSAND)
TABLE 260. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD THOUSAND)
TABLE 261. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD THOUSAND)
TABLE 262. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD THOUSAND)
TABLE 263. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD THOUSAND)
TABLE 264. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Familial Adenomatous Polyposis Treatment market report include:
  • Ambry Genetics Corporation by Tempus Company
  • Eloxx Pharmaceuticals, Inc.
  • Emtora Biosciences
  • KD Pharma Group
  • Biodexa Pharmaceuticals PLC
  • Thermo Fisher Scientific Inc.
  • Labcorp Holdings Inc.
  • PreventionGenetics
  • Olympus Corporation
  • Panbela Therapeutics, Inc.
  • FUJIFILM Holdings Corporation
  • Pentax Ricoh Imaging Company, Ltd.
  • Medtronic plc
  • Stryker Corporation
  • Recursion Pharmaceuticals, Inc.
  • BGI Genomics Co., Ltd.
  • Siemens Healthcare Private Limited
  • Eiken Chemical Co., Ltd.
  • Quest Diagnostics Incorporated
  • Beckman Coulter, Inc.
  • SENTINEL CH. SpA
  • QuidelOrtho Corporation
  • Illumina, Inc.
  • 23andMe, Inc.
  • Myriad Genetics, Inc.
  • Bayer Corporation
  • Boston Scientific Corporation
  • CONMED Corporation
  • Cook Medical LLC
  • Johnson & Johnson Services, Inc.
  • Parabilis Medicines

Table Information

Report AttributeDetails
No. of Pages198
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.29 Billion
Forecasted Market Value ( USD ) by 2030 $ 1.86 Billion
Compound Annual Growth Rate7.4%
Regions CoveredGlobal
No. of Companies Mentioned32

Related Topics

Related Reports

Familial Adenomatous Polyposis - Pipeline Insight, 2025 - Product Image

Familial Adenomatous Polyposis - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Familial Adenomatous Polyposis Pipeline Analysis Report 2025 - Product Image

Familial Adenomatous Polyposis Pipeline Analysis Report 2025

  • Report
  • 200 Pages
  • Global
From
Familial Adenomatous Polyposis Coli - Pipeline Insight, 2025 - Product Image

Familial Adenomatous Polyposis Coli - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Colorectal Cancer Diagnosis and Therapeutic Updates - Product Image

Colorectal Cancer Diagnosis and Therapeutic Updates

  • Book
Gardner Syndrome Treatment Market Report 2025 - Product Image

Gardner Syndrome Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From

About the Market

Familial Adenomatous Polyposis (FAP) is a rare genetic disorder that causes the formation of numerous polyps in the colon. These polyps can become cancerous if left untreated. As such, drugs used to treat FAP are important in the treatment of colon cancer. These drugs are typically targeted therapies, which are designed to specifically target the genetic mutation that causes FAP. Commonly used drugs include bevacizumab, cetuximab, and panitumumab. These drugs are used in combination with other treatments such as chemotherapy and radiation therapy. The Familial Adenomatous Polyposis Drug market is a small but growing market. It is driven by the increasing prevalence of FAP and the need for effective treatments. The market is expected to grow in the coming years as new treatments are developed and approved. Some companies in the market include Roche, Merck, Pfizer, and Bristol-Myers Squibb. These companies are involved in the development and marketing of drugs used to treat FAP. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.